Kaituo Pharmaceutical-B (09939): Restitution of land use rights located in Pinghu City, Zhejiang Province, China
Kaituo Pharmaceutical-B (09939) issued an announcement. On April 25, 2024, the seller Kaituo Pharmaceutical (Zhejiang) had...
Kintor Pharmaceutical Concludes Phase II Clinical Trial for Androgenic Alopecia Treatment
Kintor Pharmaceutical (HKG:9939) said it completed the Phase II clinical trials for its Androgenic Alopecia treatment GT20029 in China, according to a Sunday filing on the Hong Kong bourse. The pharma
Changes in Hong Kong stocks | Pioneer Pharmaceutical-B (09939) opens nearly 15% GT20029 to treat male hair loss, China's phase II clinical trial reached the main end
Kaituo Pharmaceutical-B (09939) rose by nearly 15%. As of press release, it rose 14.94% to HK$1, with a turnover of HK$81,000.
Pioneer Pharmaceutical-B (09939): GT20029 Chinese phase II clinical trial to treat male hair loss reached the main end
Zhitong Finance App News, Kaituo Pharmaceutical-B (09939) issued an announcement. The board of directors of the company is pleased to announce that the Chinese phase II clinical trial for topical treatment of androgenic alopecia in men with a novel proteolytic chimeric compound targeting androgen receptors has reached the main research end. The results are statistically significant and clinically significant, and the safety and tolerability are good. GT20029 Based on the results of this phase II clinical trial, the company will actively deploy clinical strategies for GT20029 follow-up, such as conducting a phase III clinical trial of male hair loss in China and US II
Develop the pharmaceutical industry's 2023 performance: explore Pico's multi-channel commercialization path and dig deeper into multi-pipeline R&D and commercial value
SUZHOU, March 29, 2024/PRNewswire/ -- On March 29, 2024, Beijing time, Kaituo Pharmaceutical (stock code: 9939.HK), a biopharmaceutical company focused on the development and industrialization of potential pioneers and best-in-class innovative drugs, announced recent business highlights and annual results for the year ending December 31, 2023. 2023 Annual Results Overview Business Overview Pico Dual Core Products Global Clinical Research and Development Continues to Advance Multiple Pipelines Reveal the Value of R&D and Commercial Cooperation Multiple Research Results Selected for Important Academic Conferences and Financial Overview Funding in Core Journals
Kaituo Pharmaceutical-B (09939) announced its 2023 annual results, with a net loss of 1.06 billion yuan, an increase of 11.2% over the previous year
Kaituo Pharmaceutical-B (09939) announced the results for the year ended December 31, 2023, and the Group has not approved the entry...
KINTOR PHARMA-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Kaituo Pharmaceutical-B (09939.HK) plans to hold a board meeting on March 28 to approve the annual results
Gelonghui March 15 | Kaituo Pharmaceutical-B (09939.HK) announced that the board of directors meeting will be held on March 28, 2024 (Thursday) to consider and approve (among other things) the annual results of the company and its subsidiaries for the year ended 31 December 2023 and their announcements.
KINTOR PHARMA-B: DATE OF BOARD MEETING
Kaituo Pharmaceutical-B (09939) published research results on c-MYC-targeting molecular gum compounds in the Nature sub-journal
The article mainly analyzes the mechanism of action of MYC in inducing resistance to CDK4/6 inhibitors by promoting PRB1 degradation, and suggests that the c-Myc degrading agent a80.2hcl can enhance the therapeutic effect of CDK4/6 inhibitors.
Study of Kintor's C-Myc Degrader Published in Subsidiary Journal of Nature
SUZHOU, China, March 14, 2024 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939.HK), a clinical-stage biotechnology company developing innovative small molecule and biological
Changes in Hong Kong stocks | Kaituo Pharmaceutical-B (09939) once fell more than 21% to a new low and was removed from the Shenzhen-Hong Kong Stock Connect list
The Zhitong Finance App learned that Kaituo Pharmaceutical-B (09939) once fell by more than 21%, and the intraday low of HK$1.03 hit a new market low. As of press release, it fell 16.03% to HK$1.1, with a turnover of HK$13.2661 million. According to the news, according to the Shenzhen Stock Exchange announcement, due to the implementation of component stock adjustments in the Hang Seng Composite Large-Cap Index, Mid-Cap Index, and Small-Cap Index, Kaituo Pharmaceutical will be removed from the Hong Kong Stock Exchange's securities list under the Shenzhen-Hong Kong Stock Connect in accordance with the relevant provisions of the “Shenzhen Stock Exchange's Shenzhen-Hong Kong Stock Connect Business Implementation Measures”, which will take effect from today. According to reports, Kaituo Pharmaceutical continued to lose money after three years of listing, and the cumulative loss amount has already exceeded
Changes in Hong Kong stocks | Kaituo Pharmaceutical-B (09939) fell by more than 10% and was eliminated, and the Hong Kong Stock Connect Index lost more than 2 billion yuan in three years
Kaituo Pharmaceutical-B (09939) fell by more than 10%. As of press release, it was down 9.7% to HK$1.49, with a turnover of HK$6.410,000.
Pharmaceutical stocks were generally good, and Pharmaceutical Biotech (02269) rose 9.6%. Institutions say the pharmaceutical sector has entered the value investment range
Jinwu Financial News | Pharmaceutical stocks are generally improving. As of press release, Pharmaceuticals (02269) has risen 9.6%, Federal Pharmaceuticals (03933) and Rongchang Biotech (09995) have both risen by more than 7%, Cinda Biotech (01801) has risen 6.7%, and Kaituo Pharmaceutical (09939) has risen 5.44%. According to the news, CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range. With the gradual stabilization of domestic policies and the fading of the innovation bubble, outstanding representatives of domestically produced innovative drugs and medical devices began to stand out under the storm. In the country of 2024
Changes in Hong Kong stocks | Kaituo Pharmaceutical-B (09939) rose more than 8%, phase III clinical trial of a drug to treat hair loss was recently approved
Kaituo Pharmaceutical-B (09939) rose by more than 8%. As of press release, it rose 7.95% to HK$1.63, with a turnover of HK$1,8021 million.
After betting on androgenic baldness alone failed, can a combination of drugs “prolong” the life of Pioneer Pharmaceutical-B (09939)?
After the market on February 1, Kaituo Pharmaceutical revealed news that the company's self-developed Kx-826 combined with minoxidil to treat male hormonal alopecia in Chinese male patients was approved by NMPA.
Changes in Hong Kong stocks | Kaituo Pharmaceutical-B (09939) rose 50% at the end of the session and had a record high turnover. Phase III clinical trial of a drug to treat hair loss was approved
Kaituo Pharmaceutical-B (09939) rose 50% at the end of the session. As of press release, it had risen 45.83% to HK$1.75, with a turnover of HK$245 million, a record high.
Pioneer Pharmaceutical-B (09939.HK): Clinical trial of KX-826 combined with minoxidil to treat AGA in men was approved by NMPA
Gelonghui, Feb. 1 | Kaituo Pharmaceutical-B (09939.HK) announced that its self-developed and potentially pioneering phase IB/III clinical trial of KX-826 combined with minoxidil to treat male androgenic alopecia (“AGA”) in Chinese adult male androgenic alopecia (“AGA”) has recently been approved by the National Drug Administration (“NMPA”) to evaluate the efficacy and safety of KX-826 combined with minoxidil in the treatment of male adult AGA patients in China. KX-826 is one of the Group's core drugs. Since its development, it has been completed in China and the US
CICC: The pharmaceutical sector has entered the value investment range. It is recommended to focus on overseas exports and opportunities to increase the localization rate
CICC released a research report saying that after more than 2 years of systematic adjustments, the pharmaceutical sector has entered the value investment range.
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
No Data